About Michael Morton

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.

ApconiX Welcomes Katie Cox to The Team

Katie joins ApconiX as a placement student for the month of July.  Katie, a third-year student from Sheffield University studying Biomedical Sciences hopes to carry on with her studies and complete a master’s degree at Sheffield after graduation. Eager to gain experience of a real-world laboratory, Katie took her tutor’s advice and applied.  Dr Stephen [...]

By |2018-07-11T09:42:42+00:00July 5th, 2018|Careers|Comments Off on ApconiX Welcomes Katie Cox to The Team

ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

Why is Time Critical to hERG Screening Data? ApconiX has worked hard to optimise our processes and is now returning over 80% of hERG screening data back to clients within one week of compound receipt.  This allows critical decisions to be made in medicinal chemistry on a full dataset of compound properties, avoiding mistakes and [...]

By |2018-06-21T16:30:26+00:00March 5th, 2018|Ion Channels|Comments Off on ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

ApconiX Welcomes Dr Karen Jones to The Team.

ApconiX is delighted to welcome Dr Karen Jones who joins us from AstraZeneca.  Karen, a talented electrophysiologist, will work with Dr Michael Morton to ensure the laboratory continues to provide an outstanding service as the demand for ion channel and cardiovascular safety screening increases. Karen graduated from the University of Liverpool with a degree in [...]

By |2018-07-11T14:36:29+00:00December 2nd, 2017|Ion Channels, Careers|Comments Off on ApconiX Welcomes Dr Karen Jones to The Team.

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

ApconiX Announce Their Alliance with PhysioStim.

The European Centre of Excellence for preclinical cardiovascular electrophysiology. The ApconiX team is pleased to announce their alliance with PhysioStim to create a new Centre of Excellence dedicated to cardiac safety studies. Both companies team up to offer a complete range of services in nonclinical cardiovascular electrophysiology. ApconiX, based at Alderley Park in the U.K. [...]

By |2018-06-20T16:06:07+00:00September 21st, 2017|Ion Channels, Press|Comments Off on ApconiX Announce Their Alliance with PhysioStim.

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel

Abstract: Background and Purpose: We aimed to characterize the pharmacology and electrophysiology of N-[3-(1H-benzimidazol-2-yl)-4-chloro-phenyl]pyridine-3-carboxamide (AZSMO-23), an activator of the human ether-a-go-go-related gene (hERG)-encoded K+ channel (Kv11.1). Experimental Approach: Automated electrophysiology was used to study the pharmacology of AZSMO-23 on wild-type (WT), Y652A, F656T or G628C/S631C hERG, and on other cardiac ion channels. Its mechanism of action [...]

By |2018-06-20T16:06:22+00:00June 20th, 2015|Ion Channels, Publications|Comments Off on Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel

Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays

Abstract: Cardiovascular-related adverse drug effects are a major concern for the pharmaceutical industry. Activity of an investigational drug at the L-type calcium channel could manifest in a number of ways, including changes in cardiac contractility. The aim of this study was to define which of the two assay technologies - radioligand-binding or automated electrophysiology - [...]

By |2018-06-20T16:43:00+00:00September 20th, 2014|Ion Channels, Publications|Comments Off on Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays

Preservation of cardiomyocytes from the adult heart

Abstract: Cardiomyocytes represent one of the most useful models to conduct cardiac research. A single adult heart yields millions of cardiomyocytes, but these cells do not survive for long after isolation. We aimed to determine whether inhibition of myosin II ATPase that is essential for muscle contraction may preserve fully differentiated adult cardiomyocytes. Using inhibitors [...]

By |2018-06-20T16:53:12+00:00November 20th, 2013|Ion Channels, Publications|Comments Off on Preservation of cardiomyocytes from the adult heart